<DOC>
	<DOCNO>NCT00449657</DOCNO>
	<brief_summary>This phase II study evaluate toxicity overall survival pulse paclitaxel concurrent thoracic radiotherapy , adjuvant gemcitabine carboplatin stage IIIA IIIB non-small cell lung cancer</brief_summary>
	<brief_title>Phase II Trial Pulsed Taxol With Concurrent Thoracic Radiotherapy , &amp; Adjuvant Chemo Stage III NSCLC</brief_title>
	<detailed_description>OBJECTIVES Primary 1 . Overall survival 2 . Tumor response use RECIST criterion Secondary 1 . Determine toxicity propose treatment patient population . 2 . Progression free survival 3 . Locoregional control 4 . Distant failure STUDY DESIGN Description Study Phase II study evaluate toxicity overall survival pulse paclitaxel concurrent thoracic radiotherapy , adjuvant gemcitabine carboplatin stage IIIA IIIB non-small cell lung cancer . Rationale Study Design The propose dos gemcitabine , carboplatin , paclitaxel , thoracic radiation therapy previously study deem safe . The design study find maximum tolerate dose ( MTD ) agent , study toxicity overall survival combination . Outcome Measures Primary Outcome Measures 1 . Overall survival 2 . Tumor response use RECIST criterion Secondary Outcome Measures 1 . Locoregional control 2 . Distant Failure 3 . Progression free survival</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Patients must : IIIA IIIB nonsmall cell lung cancer radiographic surgical staging , exclude : superior sulcus tumor , tumor associate atelectasis obstructive pneumonitis entire lung , tumor malignant pleural effusion . 2 . Patients include study base follow criterion : Patients must older 18 year old . Patients must Zubrod performance status 0 2 Patients adequate bone marrow function Patients adequate renal function Patients adequate hepatic function Patients childbearing potential must negative serum pregnancy test use effective form contraception . Patients suitable treatment radical intent use concurrent chemotherapy radiation . Patients sign approve informed consent authorization permit release personal health information . 1 . DiseaseSpecific Exclusions Superior sulcus tumor Atelectasis obstructive pneumonitis entire lung Malignant pleural effusion 2 . General Medical Exclusions Surgical candidate Patients pregnant time diagnosis Serious concomitant systemic disorder incompatible study Inability comply study and/or followup procedure Life expectancy le 12 week Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Patients septicemia severe infection . Patients circumstance permit completion study require followup Patients contraindication gemcitabine , carboplatin , paclitaxel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>